As of 2026, retatrutide has not been approved by the MHRA, FDA, EMA, or any other regulatory authority for human or veterinary use
Its common during this adjustment period to experience mild gastrointestinal symptoms such as nausea, vomiting, diarrhea, or constipation
Real numbers tell the story: Studies show that women with obesity who lose just 5-10% of body weight see a 50% improvement in ovulation rates, a 30% improvement in natural conception rates, and restoration of regular cycles in 60-70% of women with irregular periods
Some patients just need the medication, a licensed doctor review, and a simple monthly cost with nothing extra attached
The phase 3 trials also tested a 4mg maintenance dose in addition to the 9mg and 12mg doses
Specifications Downloads You may also be interested in the following product(s) Citations A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis